Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Cocrystal Pharma ( (COCP) ) has provided an update.
On September 15, 2025, Cocrystal Pharma closed a registered direct offering and concurrent private placement, raising approximately $4.75 million. The proceeds will be used for general corporate purposes and the continued development of their viral disease treatments, potentially impacting their market position and stakeholder interests.
The most recent analyst rating on (COCP) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Cocrystal Pharma stock, see the COCP Stock Forecast page.
Spark’s Take on COCP Stock
According to Spark, TipRanks’ AI Analyst, COCP is a Underperform.
Cocrystal Pharma faces significant financial challenges, with no revenue and ongoing operational losses severely affecting its stock score. The technical analysis indicates potential downward pressure, while the negative valuation metrics are concerning. However, recent corporate events provide some positive aspects, suggesting future growth potential. Overall, the company’s stock score reflects these mixed factors, indicating substantial risk with some long-term opportunities.
To see Spark’s full report on COCP stock, click here.
More about Cocrystal Pharma
Cocrystal Pharma, Inc. operates in the pharmaceutical industry, focusing on the development of novel medicines for the treatment of human viral diseases.
Average Trading Volume: 1,417,288
Technical Sentiment Signal: Sell
Current Market Cap: $16.21M
See more insights into COCP stock on TipRanks’ Stock Analysis page.